Loading...
•
Sep 30
Glaukos Q3 2025 Earnings Report
Glaukos announced strong financial results for the third quarter of 2025, with record net sales and significant year-over-year growth.
Key Takeaways
Glaukos reported record net sales of $133.5 million in Q3 2025, marking a 38% increase year-over-year. This growth was primarily driven by strong performance in the glaucoma segment, particularly in the U.S. market. The company also raised its full-year 2025 net sales guidance and provided preliminary 2026 guidance, reflecting continued positive momentum.
Record net sales reached $133.5 million in Q3 2025, an increase of 38% year-over-year.
Glaucoma net sales were a record $110.2 million, up 45% year-over-year, with U.S. Glaucoma sales increasing 57% to $80.8 million.
Gross margin was approximately 78%, and non-GAAP gross margin was approximately 84% for the quarter.
The company raised its 2025 net sales guidance to a range of $490 million to $495 million and introduced preliminary 2026 guidance of $600 million to $620 million.
Glaukos
Glaukos
Glaukos Revenue by Segment
Glaukos Revenue by Geographic Location
Revenue by Segment
Glaucoma Revenue
CapyFin.comRevenue by Geographic Location
U.S. Glaucoma Revenue
CapyFin.comInternational Glaucoma Revenue
CapyFin.com Forward Guidance
Glaukos has raised its 2025 net sales guidance and provided preliminary 2026 net sales guidance, indicating continued growth expectations.
Positive Outlook
- Raised 2025 net sales guidance to $490 million to $495 million, up from $480 million to $486 million.
- Introduced preliminary 2026 net sales guidance of $600 million to $620 million.
- Reflects continued strong momentum and successful global execution of strategic plans.
- Advancing a robust pipeline of novel, dropless platform technologies.
- Designed to meaningfully advance the standard of care and improve outcomes for patients.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the report.
- Potential impact of general macroeconomic conditions, including foreign currency fluctuations.
- Uncertainty in securing or maintaining adequate coverage or reimbursement by governmental or third-party payors.
- Lengthy and expensive clinical trial process and uncertainty of timing and outcomes from regulatory approvals.
- Risks related to protecting information systems against cyber threats and complying with data privacy laws.